Compare BC & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BC | CNTA |
|---|---|---|
| Founded | 1845 | 2020 |
| Country | United States | United Kingdom |
| Employees | 14000 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 6.1B |
| IPO Year | N/A | 2021 |
| Metric | BC | CNTA |
|---|---|---|
| Price | $80.40 | $39.62 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | ★ $83.55 | $43.17 |
| AVG Volume (30 Days) | 527.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 29.13 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,000,000.00 |
| Revenue This Year | $9.81 | N/A |
| Revenue Next Year | $5.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $54.49 | $11.55 |
| 52 Week High | $90.25 | $40.26 |
| Indicator | BC | CNTA |
|---|---|---|
| Relative Strength Index (RSI) | 48.81 | 62.46 |
| Support Level | $73.66 | $39.36 |
| Resistance Level | $84.76 | $39.86 |
| Average True Range (ATR) | 2.83 | 0.13 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 55.21 | 25.93 |
Brunswick is a leading manufacturer in the marine recreation industry. The firm has more than 60 brands delivering products across propulsion (outboard, sterndrive, and inboard engines, propulsion-related controls, rigging, and propellers), parts, accessories, and technology, and boats (including well-known brands like Boston Whaler and Sea Ray). It also owns more than 450 Freedom Boat Club locations as well as Boateka, which facilitates transactions in the used-boat market. Brunswick's focus surrounds building the innovative marine and recreational experiences, technologies, and connections supported by quality and innovation.
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.